Overview

The Use of Sugammadex in the Critically Ill

Status:
Unknown status

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

Moderate and Deep neuromuscular blockade (rocuronium administered to a train of four count 0 and post-tetanic count of 1-2) in critically ill patients needing intubation or procedures can be reversed immediately and effectively by sugammadex avoiding unnecessary paralysis in an already weakened population

Phase:

N/A

Details

Lead Sponsor:

McGill University Health Center
McGill University Health Centre/Research Institute of the McGill University Health Centre

Treatments:

Glycopyrrolate
Neostigmine
Rocuronium